title: Long-term mortality follow-up of hospital survivors of a myocardial infarction randomized to nifedipine in the SPRINT study. Secondary Prevention Reinfarction Israeli Nifedipine Trial.
abstract: This study was intended to determine the 5-year mortality of 2138 post-myocardial infarction (MI) patients who took part in the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). In the framework of the SPRINT study, 1065 patients were randomly assigned 30 mg/d nifedipine therapy, for a mean 10-month follow-up period, and 1073 received placebo. No information is available concerning treatment after the first year. One-year postdischarge mortality was 5.0% in the placebo group and 5.9% among patients receiving nifedipine (P = 0.37). Mortality rates after 5 years of follow-up in patients previously randomized to 1 year of nifedipine therapy and placebo were 18.4% and 18.3%, respectively. The 5-year mortality risk ratio associated with randomization to nifedipine over 1 year, adjusted for age, gender, past MI, angina, diabetes, hypertension, MI location, and therapy, was 1.00 (95% CI: 0.81-1.22). Our results do not support an association between nifedipine therapy and a late harmful effect on long-term mortality.
authors.affiliation: SPRINT Study Group, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Reicher-Reiss
authors.forename: S
authors.initials: S
authors.lastname: Behar
authors.forename: V
authors.initials: V
authors.lastname: Boyko
authors.forename: L
authors.initials: L
authors.lastname: Mandelzweig
authors.forename: E
authors.initials: E
authors.lastname: Kaplinsky
authors.forename: U
authors.initials: U
authors.lastname: Goldbourt
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality* / Q000517:prevention & control*; D009543:Nifedipine / Q000627:therapeutic use*; D010349:Patient Compliance; D016016:Proportional Hazards Models; D012008:Recurrence
chemical_list: D002121:Calcium Channel Blockers; D009543:Nifedipine